More Shin Nippon Biomedical Laboratories, Ltd. news
Shin Nippon Biomedical Laboratories, Ltd.TSE: 2395

Notice Regarding Distribution of Interim Dividends from Retained Earnings

Nov 9, 2026 at 9:30 PM EST · Issued by Shin Nippon Biomedical Laboratories, Ltd. via TDnet

Filed with TSE · Nov 9, 2026 at 9:30 PM EST · 1 page · English

On 6ix: 6ix.com/news/notice-regarding-distribution-of-interim-dividends-from-retained-earnings

Shin Nippon Biomedical Laboratories, Ltd. on 6ix

In the deck

  • Shin Nippon Biomedical Laboratories — H1 FY2026 Earnings Presentation29 slidesNov 10, 2026

Earlier from Shin Nippon Biomedical Laboratories

  • Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)Aug 4
  • Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in HeadacheNov 5, 2025
  • Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific MeetingJun 19, 2025
  • Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineApr 30, 2025
All Shin Nippon Biomedical Laboratories news releases↗

Follow Shin Nippon Biomedical Laboratories into a list and get an email when it puts out news.

Follow Shin Nippon Biomedical Laboratories
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer